Opexa shares skyrocket on Ph3 MS progress

Shares of Opexa Therapeutics shot up more than 60 percent this morning--taking a big gain on a relatively modest step forward on its new MS therapy Tovaxin. The developer says that it successfully completed two discussions with regulators on its late-stage study of Tovaxin. "We are very pleased with the outcome of our two recent FDA meetings regarding Tovaxin, the first ever personalized T-cell therapy for MS patients, as we believe we now have a well defined path forward for Phase 3 clinical studies," commented CEO Neil Warma. Story

Suggested Articles

Xcovery's ALK inhibitor shrank tumors in 75% of lung cancer patients, compared to 67% for Pfizer's Xalkori, the first FDA-approved drug of that class.

The FDA accepted the regulatory filing for Biogen's once-failed Alzheimer's drug, aducanumab, with plans to decide its fate by March 7, 2021.

Alexion named a chief diversity officer, while COVID-19 vaccine player has two new members of its C-suite.